PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGenetic test identifies very highest risk men for prostate cancer

BioNews

Genetic test identifies very highest risk men for prostate cancer

Published 15 June 2018 posted in News and appears in BioNews 954

Author

Charlott Repschläger

PET BioNews

Sixty-three novel gene variants linked to prostate cancer in men have been discovered...

Sixty-three novel gene variants linked to prostate cancer have been discovered. 

The 63 new variants discovered add to the 85 genetic markers already associated with this form of cancer. With the findings, the researchers devised a genetic test that could identify the top one percent of men at risk of developing the disease. One of the mutations discovered was linked to early-onset prostate cancer. 

'The reason we are particularly excited by the test is that this can be offered in general practice as a spit test to really try and identify who is most at risk of prostate cancer so we can offer them targeted screening,' said Professor Rosalind Eeles of London's Institute of Cancer Research (ICR), an author of the study, published in Nature Genetics.

Professor Eeles and her colleagues used a genome-wide association study to compare new and existing DNA data of 80,000 patients with prostate cancer with 61,000 healthy controls. 

Many of the mutations identified may be involved in immune system communication, with others linked to DNA-repair processes. 

A trial of the genetic test for prostate cancer is now being rolled out among a number of GP practices in London. It requires participants to give a saliva sample, which can then be analysed for genetic predisposition to the disease. The results could then be used to identify the men that might benefit from increased monitoring, MRI scans and biopsies. 

'This new research could help men to understand their individual genetic risk of prostate cancer, which could prompt them to speak to their GP about the disease,' said Dr Iain Frame, director of research at Prostate Cancer UK.

However, the mutations the test is screening for only account for about 28 percent of a man's risk of developing prostate cancer. The researchers suspect that the remaining cases are caused either by extremely rare mutations or an accumulation of several smaller mutations, which have no significant impact taken alone but together might trigger prostate cancer development.

In a second study, led by researchers at the University of Michigan and published in the journal Cell, researchers have identified a novel subtype of prostate cancer likely to be responsive to immunotherapy. 

Men with a mutation in both copies of the CDK12 gene appear to benefit from immunotherapy. The researchers found that about seven percent of late-stage prostate cancer patients and one percent of patients in earlier stages of the disease would be likely to respond to the treatment. 

'Immunotherapy works for a relatively small group of men with advanced prostate cancer – but when it works, it really works,' said study author Professor Johann de Bono, Regius Professor of cancer research at the ICR. 'In the future, a genetic test could help pick out men with this particular set of genetic changes, so that they can be considered for immunotherapy.'

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
8 January 2021 • 2 minutes read

Genetic basis discovered for the higher risk of prostate cancer in black men

by Dr Melania Montes Pérez

Black men present genetic variations that make them more vulnerable than white men to developing prostate cancer research revealed...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 May 2019 • 2 minutes read

Prostate cancer gene mutation raises risk of death by threefold

by Charlott Repschläger

A mutation that raises a prostate cancer patient's risk of death by threefold has been discovered...

Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
CC BY-SA 3.0
Image by Christoph Bock/Max Planck Institute for Informatics via Wikimedia Commons. Depicts a DNA molecule that is methylated on both strands on the centre cytosine.
News
19 October 2018 • 2 minutes read

Epigenetic test sorts fatal from manageable prostate cancer

by Isobel Steer

Researchers have identified a DNA methylation signature that can identify aggressive prostate cancer, with up to 92 percent accuracy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 August 2018 • 2 minutes read

Report warns against universal screening of babies' genomes

by Shaoni Bhattacharya

The universal screening of babies' genomes at birth is not 'inevitable', according to a new report from a US bioethics organisation...

PET BioNews
News
1 June 2018 • 2 minutes read

Silencing a prostate cancer gene kills tumour cells

by Dr Massimo Ganassi

A recent study identifies a new molecule as a potential target for prostate cancer therapy...

PET BioNews
News
3 May 2018 • 2 minutes read

'Master activator' gene for cancer spread found

by Dr Molly Godfrey

A gene that plays a major role in promoting metastasis — the spread of cancer around the body — has been identified...

PET BioNews
News
31 August 2017 • 2 minutes read

Liquid biopsy may help target prostate cancer treatment

by Charlotte Spicer

A new three-in-one blood test could progress personalised treatment for patients with prostate cancer...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
18 December 2015 • 3 minutes read

'Suicide gene therapy' for prostate cancer shows promise

by Dr Lone Hørlyck

A treatment for prostate cancer, combining radiotherapy and a new type of gene therapy, is both safe and effective, a study has found...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Genome-editing cells with CRISPR may affect cancer risk

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

4 July 2022 • 2 minutes read

USA scrambles to understand implications of Roe v Wade on fertility industry

4 July 2022 • 2 minutes read

Genetic and epigenetic causes of IVF embryo arrest discovered

4 July 2022 • 2 minutes read

Dutch donor-conceived people seek answers

4 July 2022 • 2 minutes read

Genetic variant increases Alzheimer's risk, especially in women

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856